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Monoclonal antibodies are increasingly being incorporated in conditioning regimens for autologous or
allogeneic hematopoietic cell transplantation (HCT). The beneﬁt of adding rituximab to autologous HCT
regimens is purportedly related to in vivo purging of clonal B cells. Randomized trials comparing the addition
(or not) of rituximab to high-dose therapy regimens are lacking. No beneﬁt of standard-dose radio-
immunotherapy-based regimens for autografting in aggressive lymphomas was seen in a randomized
controlled study. The incorporation of rituximab into allogeneic HCT regimens aims to improve responses
while reducing nonrelapse mortality resulting from acute graft-versus-host disease. The optimal dose and
administration schedule of rituximab in this setting are unknown, and potentially serious complications from
increased infections owing to prolonged (and profound) cytopenias or persistent hypogammaglobulinemia
are of concern. Radioimmunotherapy-based conditioning for allografting holds promise as a modality to
optimize tumor control and synergize adoptive immunotherapy effects, but it remains experimental at this
time. The addition of alemtuzumab to allogeneic HCT regimens is associated with prolonged lymphopenia
and impaired immune reconstitution, high relapse rates, and serious infections. The optimal dose and
schedule of alemtuzumab to avoid prolonged immune paresis remain elusive. It is anticipated that additional
monoclonal antibodies will soon become available that can be incorporated into HCT regimens after safety
and clinical efﬁcacy are demonstrated.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
The past decades witnessed signiﬁcant advances in
development of monoclonal antibodies (mAbs) for treatment
of various neoplasms [1-3]. The use of mAbs, either as
monotherapy or in combination with conventional chemo-
therapies, has become the standard of care for various
diseases [4]. These agents are also being incorporated into
conditioning regimens for autologous (auto) and allogeneic
(allo) hematopoietic cell transplantation (HCT). For high-
dose therapy (HDT) and auto-HCT, the main beneﬁts of
adding mAbs are further improved efﬁcacy, reduced relapse,
and ultimately improved cure rates. Although these are also
major reasons for using mAbs in the allo-HCT setting, other
beneﬁts, including reducing the incidence and severity of
graft-versus-host disease (GVHD), are seen as well [5].
mAbsdnamely, rituximab and alemtuzumabdalso induce
responses in corticosteroid-refractory GVHD [6-8]; however,
this effect is not the focus of the present review. Here, we
review the published literature pertaining to the use of mAbs
in HCT conditioning regimens.edgments on page 1297.
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Rituximab, a chimeric anti-CD20 mAb, is approved by the
US Food and Drug Administration and the European Medi-
cines Agency for the treatment of various subtypes of B cell
non-Hodgkin lymphoma (NHL). Rituximab exerts its func-
tion via complement-mediated cytotoxicity and antibody-
dependent cell-mediated cytotoxicity. According to the
literature, combining rituximab with HDT is feasible and
results in improved outcomes.
Rituximab in Conditioning Regimens for Autografting
HDT followed by auto-HCT is the standard of care for
chemosensitive, relapsed aggressive NHL [9]. Historically,
total body irradiation (TBI) was combined with cyclophos-
phamide or other agents as conditioning before autografting
[9]. However, transplantation centers worldwide have
moved away from TBI-based to chemotherapy-based regi-
mens, because in part to the increased risk of subsequent
myelodysplastic syndrome (MDS) and/or secondary acute
myelogenous leukemia (AML) [10]. Commonly used auto-
HCT regimens for NHL or Hodgkin lymphoma include
combination therapy with carmustine, etoposide, cytarabine,
and melphalan (BEAM); cyclophosphamide, carmustine, and
etoposide; busulfan and cyclophosphamide; carmustine,
etoposide, cytarabine and cyclophosphamide; and busulfan
plus melphalan [9,11-19]. The choice of regimen depends on
center preference and physician experience.Transplantation.
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advanced therapy, as maintenance, and in conjunction with
HCT regimens [20-24]. Randomized controlled studies
(RCTs) demonstrating the superiority of rituximab in auto-
HCT are lacking. Flohr et al. [25] combined rituximab
with dexamethasone-BEAM as a mobilization therapy in
27 patients with B cell NHL and found profound peripheral B
cell depletion without engraftment delay [25]. In that study,
rituximab was also administered on days -10 and -3 of
conditioning andwas associatedwith an overall survival (OS)
of 95% and a progression-free survival (PFS) of 77% at 16
months, respectively [25]. Khouri et al. [26] administered
premobilization rituximab (375 mg/m2 at 1 day before and
1000 mg/m2 at 7 days after chemotherapy) and high-dose
rituximab 1000 mg/m2 on days þ1 and þ8 with BEAM
before auto-HCT in 67 patients with de novo diffuse large B
cell lymphoma (DLBCL) or aggressive lymphoma with
a follicular component and reported 2-year disease-free
survival of 67% and OS of 87%. A retrospective multicenter
analysis of HDT and auto-HCT, with or without rituximab, in
patients with DLBCL and follicular NHL showed that adding
rituximab improved OS (P < .001) and event-free survival
(P < .001) [27]. In a phase 2 study, Hicks et al. [28] admin-
istered rituximab at the time of stem cell collection, as an
in vivo purging strategy and as posttransplantation mainte-
nance in patients with follicular NHL, resulting in durable
molecular remissions.
Potential concerns with rituximab use include the risk of
opportunistic infections, such as cytomegalovirus (CMV),
prolonged hypogammaglobulinemia, transient cytopenias,
and delayed platelet engraftment [20,23,25,26,29]. The Blood
and Marrow Transplantation Clinical Trials Network (BMT
CTN) conducted a randomized phase 3 trial comparing BEAM
plus rituximab and 131iodine-tositumomab (131I-T)-BEAM
conditioning for auto-HCT in patients with relapsed DLBCL
(n ¼ 224) [30]. Rituximab 375 mg/m2 was given with BEAM
on days -19 and -12. Rituximab-BEAM was accepted as the
comparator arm in this trial. At a median follow-up of 25.5
months, rituximab-BEAM was associated with a 2-year PFS
of 48.6%. Neutrophil engraftment was achieved by day þ28
in 93.5% of the patients. The comparison with 131iodine-
tositumomab-BEAM is discussed in the information to
follow. Selected studies using rituximab in auto-HCT are
summarized in Table 1. Some centers have adopted a ritux-
imab-BEAM regimen as the standard for auto-HCT in
patients with B cell NHL; however, convincing RCT-based
evidence demonstrating the superiority of rituximab in
auto-HCT remains lacking.Rituximab in Allo-HCT Conditioning Regimens
As the beneﬁts of adoptive immunotherapy mediated by
donor T cells became clearer, practice shifted toward
reducing the intensity (and toxicity) of conditioning regi-
mens for allo-HCT. Accordingly, allo-HCT using reduced-
intensity conditioning (RIC) is now offered to patients of
advanced age or with associated comorbidities who would
not have been otherwise eligible for this procedure previ-
ously [31,32]. The development of RIC regimens occurred
around the time when targeted therapies were being intro-
duced into practice; thus, combining these approaches in an
attempt to improve outcomes was a logical approach to
pursue. Lower nonrelapse mortality (NRM) has been asso-
ciated with the addition of rituximab to RIC regimens, but
these data are not based on RCTs.In 2001, Khouri et al. [5] reported encouraging results
with the addition of rituximab to a RIC regimen of ﬂudar-
abine and cyclophosphamide. In a cohort of 20 patients
(median age, 51 years; range, 31 to 68 years) who underwent
matched-sibling donor allo-HCT, administration of rituximab
was associated with a low incidence of grade II-IV acute
GVHD (aGVHD) of 20% and a 2-year disease-free survival rate
of 84% [5]. A study by the same group in 47 consecutive
patients with follicular NHL using a similar regimen
(although with a slightly different rituximab administration
schedule) found a PFS of 83% and an OS of 85% at a median
follow-up of 60 months (range, 19 to 94 months) [33]. The
incidence of grade II-IV aGVHD was only 11%, but rituximab
did not affect the incidence of chronic GVHD (cGVHD), which
was 60% [33]. The BMT CTN 0701 trial evaluating this
regimen in relapsed follicular NHL to conﬁrm the foregoing
ﬁndings has recently completed accrual [33].
A similar approach that incorporates high-dose rituximab
to ﬂudarabine and cyclophosphamide in 39 patients with
chronic lymphocytic leukemia (CLL) (74% with over-
expression of ZAP-70) reported 4-year PFS of 44% and OS of
48% [34]. The incidence of grade II-IV aGVHD was 45%,
notably higher than reported previously [5,33]. More
frequent donor lymphocyte infusion (DLI) in the CLL study
(36%) [34] versus only 2% in the follicular NHL study [33]
might explain this difference, at least in part.
A phase 2 study by Kharfan-Dabaja et al. [35] combined
CD4-guided lymphodepletion using pentostatin and phar-
macokinetically targeted i.v. busulfan plus rituximab (only
for CD20þ) in 42 patients, median age 53 years (range, 29 to
73 years), with various hematologic malignancies. Rituximab
was administered to 33 patients (79%). All patients received
peripheral blood stem cells. Updated results compiled after
the 2011 annual American Society of Hematology meeting
showed a 100-day and 2-year NRM of 2% and 17%, respec-
tively [35]. All patients (100%) achieved 50% CD3þ donor
chimerism by day þ28 (median, 87%). In disagreement with
previous reports [5,33], the incidence of dayþ100 grade II-IV
aGVHD was 59% (grade III-IV, 19%), and 2-year PFS and OS
were 55% and 68%, respectively. This regimen resulted in
early durable engraftment and low NRM. A higher number of
alternative donors and perhaps the lower cumulative dose of
rituximab used (1875 mg/m2 versus 3375 mg/m2) might
explain the higher incidence of aGVHD [5,33-35].
Recently, Michallet et al. [36] combined ﬂudarabine, 2 Gy
TBI, and rituximab (375 mg/m2 on day -5 and 500 mg/m2 on
days þ1 and þ8) in 40 patients with CLL age<65 years. One-
year and 3-year NRM were 10% and 27%, respectively. The
incidence of grade II-IV aGVHD was 44%, with a protective
effect of rituximab (P ¼ .02) based on univariate analysis. The
probability of 5-year OS was 55%. The results of this and
other studies are summarized in Table 2 [37,38].
Life-threatening complications associated with rituximab
administration in allo-HCT recipients, including an increased
risk of serious infections due to prolonged and profound
cytopenias or persistent hypogammaglobulinemia, merit
serious consideration [39]. Late-onset neutropenia has also
been linked to rituximab administration, possibly related to
arrest of maturation, apparently more likely in the presence
of a particular polymorphism of FCgRIIIa (158 V/F) [40,41].
RADIOIMMUNOTHERAPY
Radioimmunotherapy (RIT) with mAbs (typically against
CD20) conjugated to a radionuclide is effective against B cell
NHL. Two agents are currently in clinical use for indolent
Table 1
Selected Studies Incorporating Rituximab to Auto-HCT
Study Yr Type (Median Follow-up) N Diagnosis Addition of Rituximab to Regimens Rituxim Dosage Outcomes/Comments
Flinn et al. [23]* 2000 Single arm, phase 2 (240 days) 25 Follicular NHL: 44%
MCL: 28%
CLL/SLL: 20%
Lymphoplasmacytic: 4%
MZL: 4%
(1) Day 1 of cyclophosphamide mobilization
chemotherapy
(2) Seven days after platelet independence
is achieved
(1) 375 g/m2
(2) 375 g/m2
All patients engrafted. Transient neutropenia
noted. Six of 7 grafts PCR-negative.
Flohr et al. [25] 2002 Single arm, phase 2 (16 mo) 27 Follicular NHL: 44%
MCL: 19%
MZL: 7%
DLBCL: 30%
(1) Day 1 of dexamethasone-BEAMy
mobilization chemotherapy
(2) Days -10 and -3 of various conditioning
regimens
(1) 375 g/m2
(2) 375 g/m2
16-mo OS 95% and 16-mo PFS 77%
in B cell NHL
Khouri et al. [26]z 2005 Single arm, phase 2 (20 mo) 67 DLBCL: 61%
Follicular NHL: 39%
(1) Day -1 and 7 days after mobilization
chemotherapy
(2) Days þ1 and þ8 after BEAM
(1) 375 g/m2 and
1000 m m2
(2) 100 mg/m2
2-yr OS 80% and 2-yr disease-free
survival 67% in aggressive B cell NHL
Tarella et al. [27] 2008 Multicenter, retrospective
(7 yr)
349 DLBCL: 73%
Follicular NHL: 27%
(1) Four doses before PBSC collection
(2) Two additional doses after autologous HCT
(1) Not ailable
(2) Not ailable
5-yr OS 69% versus 60% without rituximab
Hicks et al. [28]*z 2008 Single arm, phase 2 (74.2 mo) 23 Relapsed follicular
NHL: 100%
(1) Before or during granulocyte-colony
stimulating factor administration for
mobilization
(2) Posttransplantation maintenance
(1) 375 g/m2
(2) Two -weekly at
375 mg 2
at 8 wk and
24 wks
77% achieved molecular remission after
auto-HCT
Vose et al. [30]*z 2011 Randomized, phase 3, multicenter
(25.5 mo)
112 DLBCL: 100% Days -19 and -12 of BEAM 375 mg 2 2-yr OS 65.6% and 2-yr PFS 48.6% in
relapsed DLBC NHL
MZL indicates marginal-zone lymphoma; PBSC, peripheral blood stem cell; SLL, small lymphocytic lymphoma.
* Study reported a formal statistical design and analysis.
y Dexamethasone-BEAM consisted of oral dexamethasone 8 mg 3 times a day on days 1-10, BCNU 60mg/m2 on day 2, etoposide 75 mg/m2 days 4-7, cytarabine 0 mg/m2 2 times a day on days 4-7, and melphalan 20 mg/m2
on day 3.
z Study formally stated and tested a hypothesis.
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Table 2
Studies Incorporating Rituximab in Allo-HCT Conditioning Regimens
Study Year Type N Diagnosis Donor Source Preparative Regimen Schedule of Rituximab
Administration
Cumulative
Rituximab Dose
GVHD Incidence NRM Survival Outcomes
Khouri et al. [5] 2001 Case series 20 Follicular NHL: 90% MRD: 100% FLU-CY Day -6: 375 mg/m2
Day þ1: 1000 mg/m2
Day þ8: 1000 mg/m2
Day þ15: 1000 mg/m2
3375 mg/m2 Acute grade II-IV: 20%
Chronic: 64%
10% 2-yr PFS: 84%
Khouri et al. [33]*y 2008 Single arm, phase 2 47 Follicular NHL: 100% MRD: 96%
MUD: 4%
FLU-CY Day -13: 375 mg/m2
Day -6: 1000 mg/m2
Day þ1: 1000 mg/m2
Day þ8: 1000 mg/m2
3375 mg/m2 Acute grade II-IV: 11%
Chronic: 60%
15% At a median follow-
up of 60 mo:
PFS: 83%
OS: 85%
Khouri et al. [34]* 2007 Single arm, phase 2 39z CLL: 100% MRD: 82%
MUD: 8%
Other: 10%
FLU-CY Day -13: 375 mg/m2
Day -6: 1000 mg/m2
Day þ1: 1000 mg/m2
Day þ8: 1000 mg/m2
3375 mg/m2 Acute grade II-IV: 45%
Chronic extensive: 58%
26% 4-yr PFS: 44%
4-yr OS: 48%
Glass et al. [38] 2008 Randomized phase 2
(rituximab versus no
rituximab)
65x DLBCL: 53% MRD: 29%
MUD: 54%
MMD: 17%
FLU-BU-CY  ATG Cycle 1, starting on
day þ21: weekly  4
Cycle 2, starting on
day þ175: weekly  4
3000 mg/m2
(1500 mg/m2 by
day þ100)
Acute grade II-IV: 73% - 1-yr PFS: 39%
1-yr OS: 49%
Pidala et al. [37] 2011 Retrospective case
series
19 CLL: 42%
Follicular: 32%
MCL: 16%
DLBC: 11%
MRD: 42%
MUD: 37%
MMD: 21%
FLU-BU  ATG Day þ1: 375 mg/m2
Day þ8: 375 mg/m2
750 mg/m2 Acute grade II-IV: 58%
Chronic: 50%
- 1-yr OS: 67%
Kharfan-Dabaja
et al. [35]*y
2011 Single arm, phase 2 42 CLL: 45%
Follicular: 14%
MCL: 10%
DLBCL: 5%
Transformed: 5%
Others: 21%
MRD: 47%
MUD: 43%
MMD:10%
Pentostatin-BU{ Day -21: 375 mg/m2
Day -14: 375 mg/m2
Day -7: 375 mg/m2
Day þ1: 375 mg/m2
Day þ8: 375 mg/m2
1875 mg/m2 Acute grade II-IV: 59%#
Chronic: 69%#
100-day: 2%#
2-yr: 17%#
2-yr PFS: 55%#
2-yr OS: 68%#
Michallet et al. [36]*y 2013 Single arm, phase 2,
multicenter
40 CLL: 100% MRD: 100% FLU-TBI Day -5: 375 mg/m2
Day þ1: 500 mg/m2
Day þ8: 500 mg/m2
1375 mg/m2 Acute grade II-IV: 44%
Chronic: 29%
1-yr: 10%
3-yr: 27%
5-yr event-free
survival: 46%
5-yr OS: 55%
BU indicates busulfan; CY, cyclophosphamide; FLU, ﬂudarabine; MMD, mismatched donor; MRD, matched-related donor; MUD, matched unrelated donor; (-), not reported/not extractable.
* Study reported a formal statistical design and analysis.
y Study formally stated and tested a hypothesis.
z Twenty-four patients had ZAP-70e expressing CLL.
x Reported outcomes based on 59 evaluable cases only.
{ Rituximab administered only to 33 patients (79%) with CD20þ-expressing lymphomas.
# Outcome included all subjects.
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Lymphoid malignancies are radiosensitive, and a distinct
inverse relationship between relapse rate and the dose of
external beam radiotherapy has been reported [42].
Although TBI has long been used for HCT conditioning in
patients with NHL, TBI-based conditioning is associated with
organ toxicity and secondary malignancies and often is not
feasible in elderly patients and patients with signiﬁcant
comorbidities [43,44]. Limited nonhematologic toxicity and
ability of radioimmunoconjugates to deliver targeted radia-
tion provided the basis for developing RIT-based HCT
conditioning regimens for NHL.
Two main approaches have evolved for applying RIT as
HCT conditioning. One uses high-dose myeloablative RIT
(with or without chemotherapy), and the other combines
standard-dose RIT with HDT before auto-HCT or with RIC
before allo-HCT.
High-Dose RIT for Auto-HCT Conditioning
Press et al. [45] pioneered the use of myeloablative RIT
conditioning for auto-HCT [45]. In early, dose-ﬁnding, phase
1 studies of 131I-T conditioning, the maximum tolerated dose
(MTD) of radiation that was safely delivered to vital organs
was 27 Gy. Further dosage escalation was limited by
cardiopulmonary toxicities [45]. Several small phase
2 studies using high-dose RIT with 131I-T alone, mainly in
patients with chemosensitive relapsed B cell NHL, demon-
strated 4-year PFS of 40% and OS of 65% (Table 3) [46-48],
with acceptable toxicities. A combination of high-dose 131I-T
(delivering radiation doses up to 27 Gy to normal organs) and
HDT as conditioning before auto-HCT [49,50] also appears to
be feasible, with 3-year PFS and OS approaching 60% to 65%
and 80% to 90%, respectively; these results compare favorably
with outcomes with high-dose RIT conditioning alone [46-
48]. However, because 131I-T emits g-radiation, its adminis-
tration is complicated by prolonged patient isolation, special
infusion equipment, caregiver/health care worker exposure
precautions, and complex dosimetry facilities.
90Y-IT, being a pure b-emitter, does not require prolonged
patient isolation or strict contact precautions. Nademanee
et al. [51], in a phase 1/2 study, combined 90Y-IT RITwith HDT
for auto-HCT in patients with B cell NHL and reported
a 2-year PFS of 78% and OS of 92% [51]. Others have also
reported encouraging outcomes in B cell NHL with high-dose
90Y-ITebased conditioning, both with [52] and without
[53,54] HDT (Table 3). Although these studies have estab-
lished the feasibility of high-dose RIT conditioning in auto-
HCT, they are limited by small sample size, heterogeneous
NHL histologies, and remission status at transplantation. RIT
conditioning was originally developed to extend HCT to
otherwise ineligible candidates for HDT and autografting,
owing either to advanced age or chemotherapy-
unresponsive disease. However, the median patient age in
most previous studies was<60 years, andmost of the studies
included chemotherapy-sensitive cases (Table 3). Retro-
spective data suggest the possible superiority of high-dose
RIT conditioning over chemotherapy and/or radiation-
containing conditioning [55]; however, no prospective RCTs
have been performed to provide conclusive evidence of this.
RIT-based auto-HCT in specialized centers is feasible and
does not appear to be associated with higher-than-expected
rates of secondary malignancies [56]; however, more data
are needed to better deﬁne the subgroup most likely to
beneﬁt from this approach. In the absence of convincing data
indicating that high-dose RIT conditioning can beadministered without a meticulous and complex dosimetric
approach, this modality likely will remain conﬁned to
centers with available expertise.
Standard-Dose RIT-Based Conditioning for Auto-HCT
To circumvent logistical challenges to the safe adminis-
tration of high-dose RIT, investigators have combined
standard-dose RIT with HDT to intensify auto-HCT condi-
tioning (Table 4). A phase 1 study by Vose et al. [57] estab-
lished the feasibility of combining 131I-T with BEAM
conditioning for auto-HCT in aggressive NHL. The MTD of
131I-T was 0.75 Gy, with 3-year PFS and OS of 39% and 55%,
respectively. Nonetheless, the myriad of subsequent pub-
lished studies evaluating standard-dose RIT for auto-HCT
(Table 4) are difﬁcult to interpret (for routine clinical use)
owing to the heterogeneity of RIT regimens used (131I-T
versus 90Y-IT), histological subtypes of NHL, and disease
status. Several uncontrolled, single-arm studies showed
impressive outcomes for relapsed, chemosensitive DLBCL
after RIT conditioning and auto-HCT [57-59]; however, the
BMT-CTN 0401 trial, which randomized patients with che-
mosensitive-relapsed DLBCL to either 131I-TeBEAM or
rituximab-BEAM conditioning, demonstrated no beneﬁt of
RIT conditioning for disease control or survival [30]. More-
over, the French cooperative group study that randomized
patients chemosensitive, relapsed aggressive NHL to condi-
tioning with 90Y-ITeBEAM or BEAM was closed prematurely
because of slow accrual [60]. Despite the small sample size
(n ¼ 43), RIT-BEAM showed a trend for improved OS (91%
versus 62%; P ¼ .05), but at the cost of a higher rate of
infection (27% versus 5%; P¼ .05) [60]. Whether the marginal
beneﬁt seen in the French study reﬂects better efﬁcacy of
90Y-IT compared with the 131I-T used in the BMT-CTN 0401
study remains unknown. The published evidence currently
does not support routine addition of standard-dose RIT to
auto-HCT conditioning in patients with relapsed, chemo-
sensitive DLBCL.
The European Mantle Cell Lymphoma Network’s MCL-3
study added RIT to auto-HCT conditioning in patients with
mantle cell lymphoma (MCL) not achieving a complete
remission after ﬁrst-line chemoimmunotherapy [61].
Compared with historical controls [62], however, no clear
beneﬁt of adding 90Y-IT was observed. RIT as an auto-HCT
conditioning component for patients with MCL undergoing
up front transplantation cannot be considered a standard
option at present.
Chemorefractory DLBCL has a poor prognosis [63]. Several
studies have suggested encouraging outcomes in patients in
this subgroup after RIT-based auto-HCT, with 2- to 3-year PFS
and OS of 39% to 63% and 55% to 67%, respectively [57,58,64].
Similarly, excellent outcomes in indolent NHL after RIT-based
auto-HCT have been reported [65,66]. We emphasize that no
randomized data exist demonstrating the superiority of RIT-
based conditioning for refractory aggressive or indolent NHL.
Accordingly, the role of standard-dose RIT conditioning for
auto-HCT remains a valid research question.
RIT-Based Conditioning for Allo-HCT
It is clear that HDT (with or without RIT) followed by
auto-HCT does not provide durable remissions in patients
with heavily pretreated, chemorefractory, or bulky NHL [67].
In these poor-risk cases, especially those of advanced age or
with comorbidities, RIC allo-HCT is frequently considered,
aiming at a potentially curative graft-versus-lymphoma
(GVL) effect. Lack of intensive chemotherapy and/or
Table 3
Prospective Studies Evaluating the Role of High-Dose Radioimmunotherapy-Based Conditioning in Auto-HCT
Study Year Type (median follow-up) n Age, Years
Median (Range)
Histology Conditioning TRM PFS OS Comments
Press et al. [45]* 1993 Phase 1 (-) 24 47 B cell NHL 131I-T or 131I anti- CD37 - - 21 mo
(median)
MTD was 27 Gy of radiation to normal vital
organs. Cardiopulmonary toxicity was
dose-limiting.
Liu et al. [47]
Press et al. [46]
1998
1995
Phase 1/2 (42 mo) 29 46 (24-59) B cell NHL 131I-T - 42% (4 yr) 68% (4 yr) In phase I of the study, 0.35, 1.7, or 7 mg/kg of
CD20 antibody was trace-labeled with 131I. Goal
was to deliver 27 Gy to normal organs.
Kaminski et al. [48] 1996 Phase 1 (-) 34 52 (27-74) B cell NHL 131I-T - - - MTD was 75 cGy whole-body radiation.
Press et al. [49]* 2000 Phase 1/2 (-) 52 47 (34-58) FL, MCL, Tx-NHL 131I-T þ CY/VP-16 - 68% (2 yr) 83% (2 yr) Patients received 1.7 mg/kg of tositumomab
labeled with an amount of 131I calibrated to a
target dose of 20-27 Gy to vital normal organs.
Gopal et al. [50] 2002 Phase 2 (-) 16 54 (35-59) MCL 131I-T þ CY/VP-16 - 61% (3 yr) 93% (3 yr) Patients received 1.7 mg/kg of tositumomab
labeled with an amount of 131I calibrated to a
target dose of 25 Gy to vital normal organs. 50%
had refractory disease.
Nademanee et al. [51] 2005 Phase 1/2 (22 mo) 31 51 (25-59.6) FL, DLBCL, MCL 90Y-IT þ CY/VP-16 3% 78% (2 yr) 92% (2 yr) 90Y dose calibrated to maintain normal organ
dose <1000 cGy. Median delivered dose was
71.6 mCi. All patients were aged <60 yr.
Ferrucci et al. [54] 2007 Phase 1 (-) 13 62 (28-73) FL, DLBCL,
Tx-NHL, MCL
90Y-IT - - - One patient developed MDS.
Devizzi et al. [53] 2008 Phase 2 (30 mo) 30 62 (29-76) B cell NHL 90Y-IT - 69% (2.5 yr) 87% (2.5 yr) All patients had uniform induction and
mobilization. Included patients in ﬁrst remission.
Winter et al. [52]* 2009 Phase 1 (33 mo) 44 54 (25-73) FL, DLBCL,
Tx-NHL, MCL
90Y-IT þ BEAM - 43% (3 yr) 60% (3 yr) 30% had refractory disease. 15 Gy was the
recommended maximum absorbed dose to vital
normal organs.
Hohloch et al. [105]* 2011 Phase 2 (50.4 mo) 16 55 (45-63) B cell NHL BEAM for ﬁrst
auto-HCT;
131I-rituximab for
second auto-HCT
33% after second
auto-HCT
64% (4 yr) 67% (4 yr) 12% had refractory disease. TRM was high after
tandem auto-HCT.
Gopal et al. [70]y 2011 Phase 1 (30 mo) 36 65 (60-76) B cell NHL 131I-T þ ﬂudarabine 7% (3-yr) 53% (3 yr) 54% (3 yr) 12% had refractory disease. 131I was calibrated
to deliver a target dose of 27 Gy to vital normal
organs.
CY indicates cyclophosphamide; FL, follicular lymphoma; MZL, marginal-zone lymphoma; Tx-NHL, transformed NHL; R, rituximab; TRM, treatment-related mortality; VP-16, etoposide; (-), not reported/not extractable.
* Study reported a formal statistical design and analysis.
y Study formally stated and tested a hypothesis.
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Table 4
Prospective Studies Evaluating the Role of Standard-Dose Radioimmunotherapy-Based Conditioning in Auto-HCT
Study Year Type (Median
Follow-up)
N Age, Years,
Median (Range)
Histology Conditioning TRM PFS OS Comments
Vose et al. [57]* 2005 Phase 1 (18.4 mo) 23 51 (26-65) Grade 3 FL,
DLBCL, MCL
131I-T þ BEAM d 39% (3-yr) 55% (3 yr) 52% of patients had refractory disease; 2 patients
developed MDS; MTD of 131I-T was 0.75 Gy.
Shimoni et al. [58] 2007 Phase 2 (17 mo) 23 55 (35-66) DLBCL, Tx-NHL,
MCL
90Y-IT þ BEAMy 17% (2 yr) 52% (2 yr) 67% (2 yr) All patients were chemorefractory.
Krishnan, et al. [106] 2008 Phase 2 (-) 41 59.6 (19-78) FL, DLBCL, Tx-NHL,
MCL
90Y-IT þ BEAMy 0% (day 100) 70% (2 yr) 89% (2 yr) 29% had refractory disease; PFS of PET-CTþ
patients was 45%.
Decaudin et al. [65]* 2011 Phase 2 (28 mo) 77 - FL, MZL 90Y-IT þ BEAMz 0% (day 100) 63% (2 yr) 97% (2 yr) All patients were chemosensitive; 2 s
cancers were seen.
Zipp et al. [66] 2011 Phase 2 (56 mo) 36 - DLBCL, FL 90Y-IT þ BEAMy - 60%-78% (5 yr) 60%-76% (5 yr) 8% s cancers at 5 yr.
Vose et al. [30]*x 2011 Phase 3 (25.5 mo) 224 56.8 DLBCL 131I-T þ BEAM
versus R-BEAM
4.9% versus
4.1% (2 yr)
48% versus
49% (2 yr)
60% versus
66% (2 yr)
BMT-CTN Trial 0401
Shimoni et al. [60]*x 2012 Phase 3 (29 mo) 22 versus 21 55 (23-67) Aggressive NHL 90Y-IT þ BEAM
versus BEAMy
- 59% versus
37% (2 yr)
91% versus
62% (2 yr)
All patients were chemosensitive; similar
engraftment kinetics in the 2 groups, but
infections in RIT group; trend toward improved
OS with RIT.
Arne et al. [61]x 2012 Phase 2 (3.2 yr) 69 57 (28-65) MCL 90Y-IT þ BEAMy 3% 55% (5 yr) 71% (5 yr) Included only MCL not in CR after ﬁrst-line
therapy; no beneﬁt of RIT over historical controls.
Briones et al. [64] 2012 Phase 2 (22.7 mo) 30 53 (25-67) DLBCL 90Y-IT þ BEAMy - 63% (2 yr) 65% (2 yr) All patients were chemorefractory.
Vose et al. [59]* 2013 Phase 2 (6 yr) 40 54 (26-75) DLBCL 131I-T þ BEAM - 70% (5 yr) 72% (5 yr) All patients were chemosensitive; 5 secondary
malignancies were reported.
FL indicates follicular lymphoma; MZL, marginal-zone lymphoma; Tx-NHL, transformed NHL; R, rituximab; TRM, treatment-related mortality; (-), not reported/not extractable.
* Study reported a formal statistical design and analysis.
y 90Y-IT dose: 0.4 mCi/kg.
z 90Y-IT dose: 0.3-0.4 mCi/kg.
x Study formally stated and tested a hypothesis.
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relapse, however, especially in refractory or bulky disease
[68]. This is because disease control in low-intensity allo-HCT
relies heavily on the GVL effect, which might take months to
establish [69]. RIT’s lack of signiﬁcant nonhematologic
toxicities and potential efﬁcacy in chemotherapy-refractory
B cell NHL provided the rationale for combining this
modality with RIC allografts to provide effective cytor-
eduction while GVL ensues [70].
Shimoni et al. [71] demonstrated the feasibility of
combining 90Y-IT RIT with ﬂudarabine-based RIC in 12 che-
morefractory patients undergoing allo-HCT (Table 5). In
a large prospective study, German investigators combined
90Y-IT RIT with ﬂudarabine and low-dose TBI-containing
nonmyeloablative conditioning [72]. The majority of their
patients (85%) had chemosensitive disease; 2-year PFS was
43%, with a high rate of aGVHD and a 2-year NRM of 45%.
Conversely, Gopal et al. [70], using a similar regimen in
chemorefractory cases (85%), reported a 2-year PFS of 31%,
with an NRM of 16%. On multivariate analysis, patients with
indolent NHL had a superior OS [70]. This observation was
conﬁrmed in the study of Khouri et al. [73], where an RIT-
based nonmyeloablative conditioning resulted in 3-year
PFS and OS >80% in patients with follicular NHL, with low
NRM.
It is important to note that although the aforementioned
studies have established the feasibility of combining RIT with
RIC regimens before allo-HCT, there are no RCTs to establish
the superiority of these regimens over RIT-free regimens.
Follow-up in published studies was relatively short, and the
majority of studies included a variety of histologies. Rates of
disease control, with one exception [73], appeared modest at
best. The sole published study evaluating higher-than-
conventional doses of 90Y-IT in RIC allo-HCT (Table 5)
showed no clear evidence of improved disease control with
more intense RIT, despite treating mostly patients with
chemosensitive NHL [74]. The low PFS might be related to
previous rituximab exposure and CD20 site blocking,
limiting optimal binding of 90Y-IT [70,75]. Whether restrict-
ing administration of 90Y-IT RIC only to cases with previous
limited rituximab exposure, targeting an alternative tumor
surface antigen with novel radiolabelled antibodies [76], or
pursuing pretargeted RIT techniques [77] would improve
outcomes remains unclear. Until randomized data estab-
lishing the superiority of RIT-based conditioning regimens in
allo-HCT become available, this strategy should be consid-
ered only within the context of clinical trials.
ALEMTUZUMAB
Alemtuzumab is a humanized mAb against the CD52
antigen, expressed mainly on normal B and T lymphocytes,
macrophages, monocytes, natural killer cells, and some
dendritic cells [78-80], that is approved for the treatment of
CLL [81,82]. Alemtuzumab has been incorporated in condi-
tioning regimens for RIC allo-HCT, mostly to decrease the
incidence and severity of aGVHD and cGVHD and to reduce
graft rejection [83,84].
The efﬁcacy of alemtuzumab has been demonstrated in
both matched related donor and matched unrelated donor
allografting [85,86]. Kottaridis et al. [85] evaluated a regimen
of ﬂudarabine, melphalan, and alemtuzumab in 44 patients
with various hematologic malignancies. Alemtuzumab
30 mg/day i.v. was administered for 5 days. Forty-two of 43
evaluable subjects (98%) achieved sustained engraftment.
Full donor chimerism was reported in 18 (58%) of 31
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with no reported grade III to IV aGVHD. NRM at 1 year was
11%. There were 7 relapses or progression, for which DLI
administration did not improve outcomes [85]. Delgado et al.
[87], in a study of 41 patients with CLL, found a 27% risk of
relapse after alemtuzumab-based regimens for allo-HCT.
NRM was 26%, mostly associated with infections [87]. The
rate of aGVHD was 41% (10% grade III-IV). These ﬁndings
demonstrate that depletion of alloreactive T cells with
alemtuzumab reduces the incidence and severity of aGVHD,
but at the cost of increased risk of relapse and opportunistic
infections.
Administration of DLI as prophylaxis to prevent relapse
after T celledepleted allografts has proven effective, partic-
ularly in cases of mixed donor chimerism [88,89].
Peggs et al. [88] reported encouraging outcomes in 22
patients with relapsed Hodgkin lymphoma who received an
alemtuzumab-based regimen and dose-escalated DLI for
mixed donor chimerism. Nineteen of the 22 patients (86%)
converted to full donor chimerism, and the incidence of
relapse was 5% at 4 years. NRM attributable to DLI was 7%,
attributed mainly to aGVHD.
A major concern related to alemtuzumab-induced T cell
depletion is the potential development of opportunistic
infections. For instance, CMV reactivation has been reported
in up to 85% of patients at risk for CMV infection [86].
Preemptive CMV therapy is effective in this setting, but
the development of deadly CMV infection remains a risk
[86]. Chakraverty et al. [86] reported an actuarial probability
of CMV disease of 6.4% at 12 months in high-risk and
intermediate-risk cases. An increased risk of bacterial
and fungal infections has also been associated with
alemtuzumab-based regimens [87]. Use of alemtuzumab-
based regimens for allo-HCT remains a reasonable option
associated with low NRM, but at the cost of a high risk of
relapse and serious opportunistic infections.
GEMTUZUMAB OZOGAMICIN
Gemtuzumab ozogamicin (GO) is a humanized
calicheamicin-conjugatedmAb targeting CD33 [90]. Previous
exposure to GO increases the risk of hepatic veno-occlusive
disease, particularly in the myeloablative HCT setting [91].
GO was withdrawn from the market in 2010 owing to a lack
of efﬁcacy and safety concerns.
deLimaetal. [92] conductedaphase1/2 trial combiningGO
with a ﬂudarabine-melphalan RIC allo-HCT regimen in
patients with CD33þ AML/MDS. GO was administered on day
-12 of conditioning. NRM (100-day)was 15%. Bornhäuser et al.
[93] administeredGO6mg/m2 onday -21 and 3mg/m2 onday
-14 before various ﬂudarabine-based or TBI-based RIC allo-
HCT regimens in 31 patients with relapsed AML. NRM was
22% at day þ100. Two-year OS was 39%, and PFS was 35%. A
phase 1 trial of GO on day -14 combined with busulfan and
cyclophosphamide myeloablative conditioning in children
with AML undergoing allo-HCT using mainly umbilical cord
cells reported a 100-dayNRMof 0% [94]. A phase 2 study using
GO7.5mg/m2 incombinationwithmyeloablative conditioning
in childrenwith AML is ongoing [94]. Overall, the combination
of GO and RIC regimens for allo-HCT appears feasible; unfor-
tunately, this drug is not commercially available.
EPRATUZUMAB
The CD22 antigen, a member of the immunoglobulin
superfamily, is a 135-kDa type I transmembrane phospho-
glycoprotein with B cellerestricted expression involved in Bcell receptor signaling, B cell survival, and homing [95,96].
The literature suggests that most B cell hematologic malig-
nancies express CD22, making it an attractive therapeutic
target. Epratuzumab is a humanized anti-CD22 mAb that
has shown activity in preclinical and clinical investigations
[96]. An antibodyedrug conjugate targeting CD22, inotuzu-
mab ozogamicin, consisting of a derivative of calicheamicin
linked to a humanized mAb against CD22, has shown
promising activity in relapsed B cell NHL [97]. There are
no published reports on epratuzumab- or inotuzumab
ozogamicinecontaining regimens for HCT.
DISCUSSION
The incorporation of mAbs into HCT conditioning regi-
mens has occurred at a slower pace than the combination of
mAbs with conventional chemotherapies, owing to the
immunologic complexities, particularly in the allo-HCT
setting. Strategies to improve efﬁcacy as well as our under-
standing of the role of B cells in the pathogenesis of GVHD
will lead to the incorporation of rituximab in allo-HCT
preparative regimens with a dual goal of improving
responses and reducing NRM [98].
In a phase 2 randomized study, Glass et al. [38] reported
an interim analysis that found no beneﬁt of adding rituximab
to an intermediate-intensity regimen for allo-HCT for
aggressive lymphomas (Table 2) in terms of the incidence of
GVHD, PFS, or OS. To our knowledge, that study still has not
been published in ﬁnal, complete form more than 4 years
later [38]. Accordingly, published RCTs are lacking, and
the existing evidence, with few exceptions [36], is from
single-arm studies or case series from single institutions
[5,33-35,37]. Of the studies summarized in Table 2, only 3
single-arm phase 2 studies focused on a particular disease
[33,34,36]. Two of those studies, which focused on CLL, used
different conditioning regimens and rituximab doses and
administration schedules [34,36], clearly limiting our ability
to compare outcomes of these trials. Thus, the optimal dose
and administration schedule remain unknown, with the allo-
HCT literature describing cumulative doses ranging from 750
to 3375 mg/m2 (Table 2).
Although results to date are encouraging, several limita-
tions must be taken into account, including the non-
randomized nature of the studies, a bias favoring enrollment
of younger patients, and subjectivity when assigning GVHD
grading, among others. In addition, reported severe, pro-
longed cytopenias with the addition of rituximab in allo-HCT
conditioning warrant careful prospective investigation to
clearly deﬁne rituximab’s therapeutic index in this setting.
Posteallo-HCT rituximab administration for B cell depletion
shows promise in modulating the incidence and intensity of
cGVHD, which might further improve long-term NRM
[99,100]. For allo-HCT, RIT-based conditioning holds great
promise as a modality to provide adequate tumor control
with low NRM, with curative GVL effects ensuing, but this
approach remains experimental at present. The development
of RIT targeting alternative tumor surface antigens [76] or
pretargeted RIT techniques could further improve posteallo-
HCT outcomes [77].
In the auto-HCT setting, no RCTs have been published
comparing the addition of rituximab to HDT versus HDT
alone. Evidence supporting a beneﬁt of adding rituximab is
purportedly related to in vivo purging of B cell infusates
[101]. Moreover, a large multicenter RCT failed to demon-
strate a beneﬁt of adding 131I-T vis-à-vis rituximab to BEAM
[30]. One major concern is the choice of rituximab-BEAM as
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been based on nonrandomized or registry data. The results of
BMT-CTN 0401 cast serious doubts on the future of RIT
conditioning in auto-HCT. The incorporation of novel anti-
bodies (eg, MEDI-551, epratuzumab, ofatumumab, brentux-
imab vedotin, GA101) in auto-HCT conditioning regimens to
improve disease control and reduce relapse is an area of
interest.
Major concerns with using alemtuzumab in allo-HCT
conditioning include prolonged lymphopenia and impaired
immune reconstitution, high risk of relapse, and serious
opportunistic infections. Strategies incorporating DLI to
reduce disease relapse are logical and apparently effective
[89]. Strategies that potentially could help reduce the inci-
dence of infections such as CMV are emerging and might
offer added beneﬁts to preemptive CMV treatment
approaches [102]. The optimal dose and administration
schedule of alemtuzumab to maintain effective GVHD
prophylaxis while avoiding prolonged immune paresis
remain elusive.
Pertaining to myeloid malignancies, GO is the only mAb
that has been incorporated into allo-HCT preparative regi-
mens for AML. Unfortunately, this agent is not commercially
available at present. A novel anti-CD33 immunotoxin,
humanized mAb M195 conjugated to recombinant gelonin
(HUM-195/rGEL), has been evaluated in a phase 1 study, and
is shown to be safe when administered in multidose cycles
[103]; this agent has not been studied in allo-HCT regimens,
however.
It is anticipated that additional mAbs will become avail-
able in the near future and will be incorporated into HCT
conditioning regimens once their safety and clinical efﬁcacy
is demonstrated.RECOMMENDATIONS AND FUTURE DIRECTIONS
Despite the aforementioned limitations, which mostly
relate to the lack of RCTs (with the exception of BMT CTN
0401), multiple factors may be considered in the decision of
whether to include mAbs in conditioning regimens for HCT.
First, some centers incorporate rituximab as part of condi-
tioning regimens for auto-HCT based on improved outcomes
from phase 2 or registry studies compared with historical
controls. RCT data are lacking, however. Careful consider-
ation, assessment, and discussion with patients are required
before including rituximab in a conditioning regimen for
auto-HCT, given the risk of prolonged cytopenias and
consequent increased risk of late infections in this setting.
More data are needed to determine the optimal dose and
administration schedule of rituximab in this setting.
Although continuous detection of circulating rituximab may
confer a protective effect against disease relapse, a recent
randomized study showed no beneﬁt of rituximab mainte-
nance after auto-HCT in patients with relapsed DLBC NHL
[104].
Second, randomized data do not support the use of
standard-dose RIT in combinationwith HDT conditioning for
either auto- or allo-HCT in patients with chemosensitive
DLBCL andMCL at the present time. The use of standard-dose
RIT in other lymphoid histologies remains investigational.
High-dose RIT (with or without HDT) performed in centers
with available expertise and dosimetric facilities appears to
be a valid option for patients with advance and/or chemo-
refractory lymphoid malignancies, but randomized data
from this setting are lacking.Third, the feasibility of incorporating rituximab in allo-
HCT conditioning regimens is supported mainly by small,
single-arm phase 2 studies, mostly from single institutions.
A preparative chemoimmunotherapy regimen of ﬂudarabine
and cyclophosphamide plus rituximab in patients with
follicular NHL may be beneﬁcial, as supported by long-term
follow-up data with encouraging outcomes, albeit non-
randomized [33]. The optimal rituximab dose and adminis-
tration schedule remain subjects of research and will be best
addressed within the context of a prospective randomized
multicenter trial targeting an individual lymphoma subtype.
Caution is advised when extrapolating data across different
diseases and/or preparative regimens. Moreover, patients
must be informed of the potential for serious infectious
complications associated with the use of rituximab in the
allograft setting, as well as the need for careful, long-term
monitoring of immune reconstitution.
Fourth, there are no randomized data supporting T cell
depletion using alemtuzumab as part of an allo-HCT
preparative regimen. Given the reduced risk of GVHD, the
use of alemtuzumab might be considered in matched unre-
lated donor or partially mismatched donor allografting, at
the cost of increased risk of disease relapse or complications
from CMV and other serious infections. Finally, we empha-
size that enrollment in clinical trials remains the most
desirable choice whenever available. Future trials incorpo-
rating these or other mAbs should focus on the development
of disease-speciﬁc regimens, preferably in the context of
multicenter prospective randomized trials with survival as
the most important endpoint, facilitated through networks
such as BMT CTN.
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